$CATALYST\ PHARMACEUTICAL\ PARTNERS,\ INC.$ 

Form 8-K March 16, 2015

#### **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

# CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

#### THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): March 16, 2015

## CATALYST PHARMACEUTICAL PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

**Delaware**(State or other jurisdiction of incorporation)

**001-33057** (Commission File Number)

**76-0837053** (I.R.S. Employer

Identification No.)

355 Alhambra Circle

**Suite 1500** 

**Coral Gables, Florida** (Address of principal executive offices)

33134

(Zip Code)

Registrant s telephone number, including area code:

(305) 529-2522

Not Applicable

Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

# Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## **Item 8.01 Other Events**

On March 16, 2015, the Company issued a press release announcing its results of operations for the fourth quarter and year ended December 31, 2014. A copy of the press release is attached hereto as Exhibit 99.1.

## Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press release issued by the Company on March 16, 2015.

2

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceutical Partners, Inc.

By: /s/ Alicia Grande Alicia Grande Vice President, Treasurer and CFO

Dated: March 16, 2015